Course Directors:
Brooks D. Cash, MD, FACG
William D. Chey, MD, FACG

Up to 3.25 hours of CME & 3.25 MOC points

1:45 pm  Welcome and Introductions
Brooks D. Cash, MD, FACG, and William D. Chey, MD, FACG

1:50 pm  Functional Dyspepsia: Current Pharmacologic Approaches
William D. Chey, MD, FACG
Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.

2:10 pm  Contemporary Review of PPI Therapy: What You and Your Patients Need to Know
Stuart J. Spechler, MD, FACG
Discuss the clinical evidence for the use of PPIs in a variety of clinical scenarios, and review current evidence regarding short- and long-term safety of PPIs.

2:30 pm  Approach to Symptomatic Diverticular Disease
Lisa L. Strate, MD, MPH, FACG
Describe the various presentations of symptomatic diverticular disease, and review current therapeutic approaches.

2:50 pm  Antibiotic Prophylaxis for the Gastroenterologist
Michelle A. Anderson, MD
Explain the evidence for and against the application of antibiotic prophylaxis in patients with gastroenterological diseases or undergoing endoscopic procedures.

3:10 pm  Q & A

3:25 pm  Break

3:40 pm  Pharmacologic Approach to Chronic Constipation and IBS-C
Brooks D. Cash, MD, FACG
Define current and emerging pharmacologic treatment options for constipation, including chronic idiopathic constipation, opioid-induced constipation, and IBS-C.

4:00 pm  Medical Management of Fatty Liver Disease
Phillip K. Henderson, DO
Discuss the issues and interventions currently available for the management of patients with fatty liver disease, with a focus on available pharmacologic approaches.

4:20 pm  Chemoprevention for Gastrointestinal Malignancies
John M. Inadomi, MD, FACG
Identify the evidence for and against chemoprevention for malignancies of the gastrointestinal tract and provide recommendations for appropriate use.
4:40 pm    **Personalized IBD Management: Best Practices for Therapeutic Drug Monitoring and for Managing Treatment Failures**  
*David T. Rubin, MD, FACG*
Outline therapeutic drug monitoring in IBD patients, and how to optimize immunosuppressive drug therapy with regard to adjusting therapy in class or switching classes of biologics.

5:00 pm    **Q & A**

5:15 pm    **Course Adjourns**